A new nasal spray that delivers a peptide to the right part of the brain can treat depression and holds promise as a potential alternative therapeutic approach, scientists say.
Lead researcher Dr Fang Liu from the Centre for Addiction and Mental Health (CAMH) in Toronto previously developed a protein peptide that provided a highly targeted approach to treating depression that she hopes will have minimal side effects.
- J&K: Students Suffer As Schools Along LOC Forced To Shut Amid Firing
- Jayalalithaa’s Health: AIADMK Women Supporters Continue Special Prayers For CM
- HTC Desire 10 Lifestyle First Look Video
- Fissures Remain Within Samajwadi Party: All You Need To Know
- Big Cheer For Delhi-Noida Commuters, DND Flyway Becomes Toll Free
- PM Modi Meets New Zealand Prime Minister John Key
- Ex-Arunachal CM Kalikho Pul Left Behind “Secret Notes” Before He Was Found Hanging: Rajkhowa
- Big Relief For Former Karnataka CM BS Yeddyurappa: Here’s Why
- Missing For Three Days, JNU Student Found Dead In Hostel Room
- Bigg Boss 10: Review Of October 25 Episode
- Delhi Government’s Rs 200 Crore Riverfront Plan: Find Out More
- School in Jammu & Kashmir’s Bandipore District Set on Fire
- Ajay Devgn On The Making Of Shivaay: Exclusive Interview
- Bodies Of Maoists Killed In Malkangiri Encounter, One Of The Biggest Such Operations
The peptide was just as effective in relieving symptoms when compared to a conventional antidepressant in animal testing. However, the peptide had to be injected into the brain. Taken orally, it would not cross the blood-brain barrier in sufficient concentrations.
“Clinically, we needed to find a non-invasive, convenient method to deliver this peptide treatment,” said Liu. The nasal delivery system, developed by US company Impel NeuroPharma, was shown to deliver the peptide to the right part of the brain. It also relieved depression-like symptoms in animals.
“This study marks the first time a peptide treatment has been delivered through nasal passageways to treat depression,” said Liu, Professor in the University of Toronto’s Department of Psychiatry. The peptide treatment interferes with the binding of two dopamine receptors – the D1 and D2 receptor complex.
Liu’s team had found that this binding was higher in the brains of people with major depression. Disrupting the binding led to the anti-depressant effects. The peptide is an entirely new approach to treating depression, which has previously relied on medications that primarily block serotonin or norepinephrine transporters.
Depression, the most common form of mental illness, is one of the leading causes of disability globally. More than 50 per cent of people living with depression do not respond to first-line medication treatment, researchers said. The study appears in the journal Neuropsychopharmacology.